152 related articles for article (PubMed ID: 35811355)
1. Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study.
Haine AI; Notenboom CMAW; Tan LVP; Ruiter R; van der Deure WM
Pharmacol Res Perspect; 2022 Aug; 10(4):e00985. PubMed ID: 35811355
[TBL] [Abstract][Full Text] [Related]
2. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
3. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
Lansinger OM; Biedermann S; He Z; Colevas AD
J Clin Oncol; 2021 Nov; 39(32):3583-3590. PubMed ID: 34357780
[TBL] [Abstract][Full Text] [Related]
4. Impact of histamine-2 antagonist shortage on the incidence of hypersensitivity reactions to paclitaxel: a reconsideration of premedication protocols in France (PACLIREACT Study).
Strobbe G; Gaboriau L; Abelé M; Villain A; Aelbrecht-Meurisse C; Carnot A; Le Deley MC; Léguillette C; Feutry F; Sakji I; Marliot G
Eur J Clin Pharmacol; 2023 Sep; 79(9):1229-1238. PubMed ID: 37438439
[TBL] [Abstract][Full Text] [Related]
5. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
[TBL] [Abstract][Full Text] [Related]
6. The added value of H
Cox JM; van Doorn L; Malmberg R; Oomen-de Hoop E; Bosch TM; van den Bemt PMLA; Boere IA; Jager A; Mathijssen RHJ; van Leeuwen RWF
Br J Cancer; 2021 May; 124(10):1647-1652. PubMed ID: 33762718
[TBL] [Abstract][Full Text] [Related]
7. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy.
Xiao D; Yang Z; Shi Y; Yang W; Zhang Y
Expert Rev Clin Pharmacol; 2024; 17(5-6):525-532. PubMed ID: 38652518
[TBL] [Abstract][Full Text] [Related]
8. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Premedication Protocol without Ranitidine for Taxane Regimen: A Multicenter Non-Randomized Historical Controlled Study.
Chantharakhit C; Ruchakorn T; Mungkornkaew S; Amorntrakoon P; Tassanamethee S; Theeratrakul P; Sujaritvanichpong N
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1331-1336. PubMed ID: 35485693
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.
Chen FC; Wang LH; Zheng XY; Zhang XM; Zhang J; Li LJ
Oncotarget; 2017 Mar; 8(12):19236-19243. PubMed ID: 27911278
[TBL] [Abstract][Full Text] [Related]
11. Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions.
Jao ME; Indorf AL; Segal EM; Miske A; Eaton KD; Marsolini T; Ghuman S
J Oncol Pharm Pract; 2024 Jan; 30(1):105-111. PubMed ID: 37021579
[TBL] [Abstract][Full Text] [Related]
12. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
Kloover JS; den Bakker MA; Gelderblom H; van Meerbeeck JP
Br J Cancer; 2004 Jan; 90(2):304-5. PubMed ID: 14974481
[TBL] [Abstract][Full Text] [Related]
13. Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study.
Montero Pérez O; Martinez Benavides J; González Fernandez T; Guerra Prio S; Romero Domínguez R; Mesía Nin R; Clopés Estela A
Expert Rev Clin Pharmacol; 2023; 16(9):877-883. PubMed ID: 37477611
[TBL] [Abstract][Full Text] [Related]
14. Histamine-2 (H
Foreman E; Polwart C; Walker A; Chambers P
Br J Clin Pharmacol; 2022 Sep; 88(9):4191-4198. PubMed ID: 35470452
[TBL] [Abstract][Full Text] [Related]
15. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.
Barroso-Sousa R; Vaz-Luis I; Di Meglio A; Hu J; Li T; Rees R; Sinclair N; Milisits L; Leone JP; Constantine M; Faggen M; Briccetti F; Block C; Partridge A; Burstein H; Waks AG; Tayob N; Trippa L; Tolaney SM; Hassett MJ; Winer EP; Lin NU
Oncologist; 2021 Nov; 26(11):927-933. PubMed ID: 34472667
[TBL] [Abstract][Full Text] [Related]
16. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
[TBL] [Abstract][Full Text] [Related]
17. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
18. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
19. Hypersensitivity reaction to paclitaxel: nursing interventions.
Myers JS
Clin J Oncol Nurs; 2000; 4(4):161-3. PubMed ID: 11261096
[TBL] [Abstract][Full Text] [Related]
20. Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer.
Jeerakornpassawat D; Suprasert P
Int J Gynecol Cancer; 2017 Oct; 27(8):1794-1801. PubMed ID: 28704328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]